Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novocure Ltd Ord Sh (NQ: NVCR ) 19.11 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Novocure Ltd Ord Sh < Previous 1 2 3 4 5 6 7 Next > Novocure to Report Second Quarter 2024 Financial Results July 01, 2024 From Novocure Via Business Wire METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival June 03, 2024 From Novocure Via Business Wire Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon May 02, 2024 From Novocure Via Business Wire NovoCure Ltd. (NASDAQ: NVCR) Leading the Way in Thursday Trading Based on Percentage Gain January 18, 2024 Via Investor Brand Network Novocure Reports First Quarter 2024 Financial Results May 02, 2024 From Novocure Via Business Wire Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 April 24, 2024 From Novocure Via Business Wire Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 April 05, 2024 From Novocure Via Business Wire Novocure to Report First Quarter 2024 Financial Results April 01, 2024 From Novocure Via Business Wire METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer March 27, 2024 From Novocure Via Business Wire INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO March 11, 2024 From Novocure Via Business Wire Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update February 22, 2024 From Novocure Via Business Wire Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer January 18, 2024 From Novocure Via Business Wire Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma January 09, 2024 From Novocure Via Business Wire Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update January 08, 2024 From Novocure Via Business Wire Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer January 04, 2024 From Novocure Via Business Wire Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference December 27, 2023 From Novocure Via Business Wire Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability November 28, 2023 From Novocure Via Business Wire Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference November 21, 2023 From Novocure Via Business Wire Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting November 10, 2023 From Novocure Via Business Wire Novocure Reports Third Quarter 2023 Financial Results October 26, 2023 From Novocure Via Business Wire Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023 October 15, 2023 From Novocure Via Business Wire Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program October 12, 2023 From Novocure Via Business Wire NovoCure Limited (NASDAQ:NVCR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing October 10, 2023 San Diego, CA -- (SBWIRE) -- 10/10/2023 -- An investigation was announced for investors in shares of NovoCure Limited (NASDAQ:NVCR) concerning potential breaches of fiduciary duties by certain... Via SBWire Novocure to Report Third Quarter 2023 Financial Results October 02, 2023 From Novocure Via Business Wire Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting September 29, 2023 From Novocure Via Business Wire Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer September 08, 2023 From Novocure Via Business Wire Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies August 29, 2023 From Novocure Via Business Wire Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer August 28, 2023 From Novocure Via Business Wire Novocure to Participate in Upcoming Investor Conferences August 25, 2023 From Novocure Via Business Wire The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR) August 17, 2023 From The Law Offices of Frank R. Cruz Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.